Levetiracetam: clinical use
Evidence-based neurology checklist on levetiracetam: clinical use: Mode of action Levetiracetam is an S-enantiomer derivative of pyrrolidine acetamide It binds to the synaptic vesicle protein 2A (SV2A): this reduces the rate of vesicle release It may also reverse GABA and glycine currents…
Mode of action
- Levetiracetam is an S-enantiomer derivative of pyrrolidine acetamide
- It binds to the synaptic vesicle protein 2A (SV2A): this reduces the rate of vesicle release
- It may also reverse GABA and glycine currents
Adjunctive indications
Monotherapy indications
Indications for intravenous use
Dosing
Teratogenicity
Neuropsychiatric adverse events (NSAEs)
Neurological side effects
Systemic side effects
References
- Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008; 4:507-523.
- Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70:607-616.
- Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 2010; 35:392-415.
- Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80:400-405.
- Fujikawa M, Kishimoto Y, Kakisaka Y, et al. Obsessive-compulsive behavior induced by levetiracetam. J Child Neurol 2015; 30:942-944.
- And 17 more. Subscribe to see the full list
